Slovensko -
slovenčina -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
gelofusine
b.braun melsungen ag, nemecko - Želatínové látky - 76 - infundibilia
Slovensko -
slovenčina -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
elidel 10 mg/g krém
viatris healthcare limited, Írsko - pimekrolimus - 46 - dermatologica
Slovensko -
slovenčina -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
berinert 500 iu
csl behring gmbh, nemecko - c1-inhibítor, derivát plazmy - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
Slovensko -
slovenčina -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
beriate 2000 iu
csl behring gmbh, nemecko - koagulačný faktor viii - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
Slovensko -
slovenčina -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
berinert 1500 iu
csl behring gmbh, nemecko - c1-inhibítor, derivát plazmy - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
Slovensko -
slovenčina -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
fibryga
octapharma (ip) sprl, belgicko - Ľudský fibrinogén - 75 - substitutio sanguinis (a krvnÉ derivÁty)
Európska únia -
slovenčina -
EMA (European Medicines Agency)
onureg
bristol-myers squibb pharma eeig - azacitidín - leukémia, myeloidná, akútna - antineoplastické činidlá - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).
Európska únia -
slovenčina -
EMA (European Medicines Agency)
ronapreve
roche registration gmbh - casirivimab, imdevimab - covid-19 virus infection - imunitný séra a imunoglobulíny, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. pozri časti 4. 4 a 5.